Vivreon Biosciences, LLC
7558 Trade St.
San Diego, CA 92121
Vivreon Biosciences – NIA SBIR # PAS-18-187
Vivreon Biosciences is pleased to apply for NIA SBIR Solicitation #PAS-18-187. Vivreon Biosciences is an
innovative life sciences company that is developing a series of novel small molecule, Ca2+ channel inhibitors
for the treatment of Alzheimer's disease (AD). Our lead compound series achieves neuroprotection by an
entirely new mechanism – inhibition of Ca2+ release-activated Ca2+ (CRAC) channels to block microgliosis.
Vivreon seeks NIA funding to bridge the gap between discovery and development. We will perform a series of
functional safety pharmacology and in vitro efficacy screens to identify promising candidate compounds in our
library of small molecule CRAC channel inhibitors. Upon successful completion of the program, our preclinical
candidate will be the first to specifically target the CRAC pathway for neuroprotection in AD, thus comprising
an entirely new tool in the battle against AD.
Vivreon has discovered a lead compound series with oral bioavailability that penetrates into the central
nervous system (CNS) very efficiently, shows no neurotoxicity in the Irwin test of CNS integrity, and
demonstrates neuroprotection in a mouse model of microgliosis (experimental autoimmune encephalitis). The
lead series inhibits microgliosis by blocking CRAC channel activity with nM potency; suppressing M1-like NF-
¿B activity, while preserving M2-like phagocytosis. We will now test select candidates from our lead compound
series in innovative safety and efficacy screens using screening technology from patient-derived induced
pluripotent stem cells (iPSCs). iPSCs will first be grown and differentiated into microHearts and screened for
functional safety pharmacology to detect potential cardiac toxicity liabilities. Finally, iPSCs from persons with
Alzheimer's disease will be differentiated into microglia-like cells to monitor the anti-neuroinflammatory
capacity of our candidate drugs. The final aim for this proposal is the preliminary preclinical characterization of
the first CRAC channel inhibitor for AD therapy and identification of key inflammatory cytokines that may be
used as surrogate biomarkers for target engagement in future clinical studies.